Efpeglenatide
- Generic Name
- Efpeglenatide
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1296200-77-5
- Unique Ingredient Identifier
- 3M1V5Z2270
- Background
Efpeglenatide is under investigation in clinical trial NCT03713684 (Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)).
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 908
- Registration Number
- NCT03684642
- Locations
- 🇺🇸
Investigational Site Number 8400009, Los Angeles, California, United States
🇺🇸Investigational Site Number 8400059, Skokie, Illinois, United States
🇺🇸Investigational Site Number 8400061, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath